CRISPR-Based Therapy Analytical Development Summit 2023
Biopharma’s definitive industry-focused forum for learning how to design, validate and implement robust analytical tools that demonstrate safety and efficacy of novel CRISPR-based therapeutics in vivo and ex vivo.
Our Delegates were Immersed in a comprehensive three-day event filled with valuable opportunities to expanding their knowledge and network with industry leaders. Through engaging in new data, focused group discussions, and in-depth case studies, they had the chance to connect with influential companies spearheading CRISPR-based therapies. Delegates too advantage of the diverse insights shared in the talks and panels to optimize analytics and maximize learnings in round table discussions and Q&A sessions.
A taste of the of the key takeaways and industry insights shared at the 2023 meeting:
Analytical techniques in manufacturing: Acquiring unique insights into the pivotal analytical techniques employed in the manufacturing process, particularly for automation of in vivo CRISPR-based products. Understand the rationale behind using Good Manufacturing Practice (GMP) materials, enabling you to make more informed decisions.
Retrospective analysis of clinical trials: Engages in a retrospective analysis of case studies from the first cohort of CRISPR edited products in clinical trials. By studying these real-world examples, you will gain valuable knowledge to optimize trial design for your CRISPR product
Up to date CRISPR regulatory guidance: Stay informed about the most recent regulatory guidance and overcome the operational challenges faced during the early stages of clinical trials. This understanding will aid in the development and optimization of your CRISPR therapy, ensuring it complies with regulatory standards
Optimizing CRISPR-complex characterization: discover novel data and techniques that optimize the characterization of the CRISPR-complex. Learn about the justifications for assay selection in research, and the techniques utilized to develop a reference standard potency assay
Comprehensive off-target assessment: Explore stipulated lower limit of detection values for off-target editing using CRISPR technology and incorporate this a comprehensive next-generation sequencing approach. Utilize predictive analytics to assess off-target effects, leading to improved precision and safety in prospective CRISPR-based therapies
Delegates Maximized exposure, leveraged new insights and engaged with other industry experts in 4+hours of dedicated networking time and indulged in the personal experiences of thought leaders in the analytical development field.